Shinpoong Pharmaceutical신풍제약
019170 · KOSPI · ₩019170 · 신풍제약
- Market cap
- ₩443B
- Enterprise value
- ₩382B
- P/E
- —
- P/B
- 1.6×
- Dividend yield
- 0.0%
- ROE
- −0.3%
- Net margin
- −0.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−46.3% from the high
₩6,310Today: ₩8,370 – ₩8,570₩15,750
Returns
- 1W−7.8%
- 1M−8.7%
- 3M+16.4%
- 6M−29.0%
- YTD−39.7%
- 1Y−46.1%
- Volume today
- 169,092
- 0.4× the 20-day average
- Traded today
- ₩1.4B
- Listed shares
- 52,418,522
- EPS (12 months)
- −₩16
- Earnings yield −0.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumWeak-8.5% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Shinpoong Pharmaceutical stock overview
Shinpoong Pharmaceutical (신풍제약, KRX: 019170) is listed on KOSPI, in the Biotech & Pharma sector. Shin Poong Pharm is a South Korean company that manufactures and sells pharmaceutical products, operating in a single business segment. Its shares closed at ₩8,460 on Oct 28, 2026, up 1.32% on the day, giving it a market value of ₩443B.
Key facts
- Market cap
- ₩443B
- Sector
- Biotech & Pharma
- Latest price change
- +1.32%
- As of
- Oct 28, 2026
- Main business
- Shin Poong Pharm is a South Korean company that manufactures and sells pharmaceutical products, operating in a single business segment.
Quick answers about Shinpoong Pharmaceutical
- What does Shinpoong Pharmaceutical do?
- Shin Poong Pharm is a South Korean company that manufactures and sells pharmaceutical products, operating in a single business segment. Its main products include prescription drugs such as Medicutton injection, Hyal injection, Brefra tablets, and Ezero tablets, alongside a malaria treatment, Piramax. Its production is based at its Ansan plant, and it also has facilities at Osong, Anyang research institute, and Vietnam.
- What is the market cap of Shinpoong Pharmaceutical?
- The market capitalisation of Shinpoong Pharmaceutical was ₩443B at the close on Oct 28, 2026.
- Who are the largest shareholders of Shinpoong Pharmaceutical?
- According to the latest official filings, the largest reported holders are VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.91%, as of Jul 31, 2026); VANGUARD DEVELOPED MARKETS INDEX FUND (0.60%, as of Jun 30, 2026); National Pension Service (0.39%, as of Dec 31, 2025).
- When is the next earnings report from Shinpoong Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Shinpoong Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Shinpoong Pharmaceutical?
- Yes. The National Pension Service held 0.39% of Shinpoong Pharmaceutical shares as of Dec 31, 2025.
Company profile
Shin Poong Pharm is a South Korean company that manufactures and sells pharmaceutical products, operating in a single business segment. Its main products include prescription drugs such as Medicutton injection, Hyal injection, Brefra tablets, and Ezero tablets, alongside a malaria treatment, Piramax. Its production is based at its Ansan plant, and it also has facilities at Osong, Anyang research institute, and Vietnam.
Written by AI from the company's latest annual report.
- Korean name
- 신풍제약
- Sector
- Biotech & Pharma
- CEO
- 유 제 만
- Founded
- Jul 1986
- Listed
- Jan 1990
- Listed shares
- 52,418,522
- Fiscal year ends
- Month 12
- Website
- www.shinpoong.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Major management matter relevant to investorsOct 22, 2026
- Major management matter relevant to investorsSep 15, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Disclosure of Corporate Governance ReportMay 29, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Shinpoong Pharmaceutical / 신풍제약 / 019170 / KRX:019170
Source: KRX statistical information